Integra LifeSciences (IART) vs. VWR (VWR) Head-To-Head Analysis

VWR (NASDAQ: VWR) and Integra LifeSciences (NASDAQ:IART) are both mid-cap medical equipment, supplies & distribution – nec companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for VWR and Integra LifeSciences, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
VWR 0 2 1 0 2.33
Integra LifeSciences 0 4 6 0 2.60

VWR currently has a consensus target price of $29.00, indicating a potential downside of 12.78%. Integra LifeSciences has a consensus target price of $53.33, indicating a potential upside of 10.51%. Given Integra LifeSciences’ stronger consensus rating and higher probable upside, analysts plainly believe Integra LifeSciences is more favorable than VWR.

Valuation and Earnings

This table compares VWR and Integra LifeSciences’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
VWR $4.51 billion 0.97 $148.20 million $1.14 29.17
Integra LifeSciences $992.08 million 3.82 $74.56 million $0.61 79.11

VWR has higher revenue and earnings than Integra LifeSciences. VWR is trading at a lower price-to-earnings ratio than Integra LifeSciences, indicating that it is currently the more affordable of the two stocks.


This table compares VWR and Integra LifeSciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
VWR 3.27% 15.90% 4.86%
Integra LifeSciences 4.52% 16.35% 6.83%

Insider and Institutional Ownership

96.7% of VWR shares are held by institutional investors. Comparatively, 87.6% of Integra LifeSciences shares are held by institutional investors. 35.5% of VWR shares are held by insiders. Comparatively, 21.5% of Integra LifeSciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.


Integra LifeSciences beats VWR on 8 of the 13 factors compared between the two stocks.

VWR Company Profile

VWR Corporation is a provider of product and service solutions to laboratory and production customers. The Company offers a portfolio of branded and private label laboratory products, services and solutions to the life science, general research and applied markets. The Company operates in two segments: Americas and EMEA-APAC. The Americas segment consists of operations located principally in the United States and Canada, as well as in Puerto Rico, Mexico and select countries in Central and South America, including Costa Rica, Brazil, Argentina and Chile. As of December 31, 2016, the Americas segment included 67 facilities located in eight countries. As of December 31, 2016, the EMEA-APAC segment consisted of its operations located principally in Europe, as well as in certain Asia-Pacific countries, and included 110 facilities located in 26 countries. The Company’s portfolio includes chemicals, reagents, consumables, durable products and scientific equipment and instruments.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.

Receive News & Ratings for VWR Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VWR Corporation and related companies with's FREE daily email newsletter.

Leave a Reply